Gossamer Bio (GOSS) Sees Strong Analyst Confidence Amid Seralutinib Progress and Upcoming PROSERA Data

With strong 1-year returns and upside potential, Gossamer Bio, Inc. (NASDAQ:GOSS) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026.

Amid the company’s continued efforts to advance seralutinib across two late-stage pulmonary hypertension programs, analyst confidence in Gossamer Bio, Inc. (NASDAQ:GOSS) remains high.

By the end of Q3 2025, Gossamer Bio, Inc. (NASDAQ:GOSS) confirmed completion of enrollment in its global Phase 3 PROSERA study for pulmonary arterial hypertension, with 390 patients enrolled. Management reported the double-blind, placebo-controlled trial evaluating seralutinib on top of background therapy, with a primary endpoint focused on six-minute walk distance at 24 weeks.

Meanwhile, Gossamer Bio, Inc. (NASDAQ:GOSS) expects topline data from PROSERA to come out in February 2026. At the same time, the company reported activation of the first clinical site for its registrational Phase 3 SERANATA study in pulmonary hypertension associated with interstitial lung disease. With this, the company sees seralutinib’s clinical scope broadening into a second indication.

Amid this clinical progress, Gossamer Bio, Inc. (NASDAQ:GOSS) has received positive analyst sentiment. Piper Sandler analyst Yasmeen Rahimi reiterated a “Buy” rating on December 9, 2025, while setting a $15.00 price target. Earlier, on November 19, 2025, the company received a “Buy” rating and a $10.00 price target from H.C. Wainwright analyst Patrick Trucchio. Trucchio cited the steady advancement of both PROSERA and SERANATA, viewing the upcoming PAH readout and expansion into PH-ILD as key milestones reflecting confidence in seralutinib’s long-term potential.

Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage biopharmaceutical company, develops seralutinib to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

While we acknowledge the potential of GOSS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Cheap Gold Stocks to Buy Now and 15 Best AI Stocks to Watch in December 2025.

Disclosure: None.